Core Viewpoint - The announcement details the expected daily related transactions for the year 2026 by Baotai Biopharmaceutical Co., Ltd., emphasizing that these transactions are necessary for normal business operations and do not harm the interests of the company or minority shareholders [2][10]. Group 1: Daily Related Transactions Overview - The expected daily related transactions do not require shareholder meeting approval, as they fall within the board's authority [5]. - The board of directors approved the expected daily related transactions for 2026 during a meeting held on December 29, 2025, with non-related directors voting unanimously in favor [3]. - Independent directors also reviewed and approved the expected transactions, confirming that they align with the company's operational needs and adhere to principles of fairness and market pricing [4]. Group 2: Transaction Amounts and Categories - The expected transaction amounts for 2026 are presented in ten thousand yuan, with specific categories including leasing properties, purchasing technical services, and selling goods to related parties [6][8]. - The transactions are based on voluntary, equal, and mutually beneficial principles, with prices set according to market rates [9]. Group 3: Purpose and Impact of Transactions - The related transactions are essential for the company's normal production and operations, serving as a means to optimize resource use and reduce operational costs [10]. - The pricing policies for these transactions strictly follow principles of openness, fairness, and equivalence, ensuring no adverse effects on the company's ongoing operations, profitability, or asset independence [10].

Group 1 - The company plans to use idle self-owned funds for entrusted wealth management to improve fund utilization efficiency and increase investment returns for the company and its shareholders [3][4][9] - The total amount for this investment is not to exceed RMB 500 million, with a rolling use of funds allowed within the authorization period from January 1, 2026, to December 31, 2026 [4][7] - The investment will focus on low-risk, high-liquidity financial products, including but not limited to deposits, structured deposits, and bank wealth management products [5][7] Group 2 - The company has completed the necessary approval procedures for the investment plan, which was approved by the board of directors on December 29, 2025, and does not require shareholder meeting approval [2][7] - The company will implement strict risk control measures, including regular assessments of investment products and timely responses to any adverse factors [8][26] - The investment is expected to enhance the efficiency of idle funds and generate additional returns without affecting the company's normal operations [9][27] Group 3 - The company also plans to use part of the temporarily idle raised funds for cash management, with an investment limit of up to RMB 200 million [14][16] - The cash management period is set from January 1, 2026, to December 31, 2026, allowing for rolling use of funds within this limit [16][24] - The cash management will focus on safe, liquid, and principal-protected investment products, ensuring compliance with relevant regulations [19][21] Group 4 - The company has established a robust framework for managing raised funds, ensuring that the cash management does not affect the planned investment projects or the company's normal operations [15][27] - The independent directors have unanimously agreed that the cash management plan aligns with the company's operational needs and does not harm the interests of shareholders [31][37] - The expected daily transactions with related parties for 2026 are estimated to be no more than RMB 14 million, ensuring fair pricing and compliance with market principles [33][36]

Group 1 - The company held its 19th meeting of the 6th Board of Directors on December 28, 2025, via communication voting, with all 7 directors participating [2][3] - The board approved the proposal for expected daily related party transactions for 2026, with a total estimated transaction amount of 22 million RMB [3][31] - The board also approved the convening of the company's first extraordinary general meeting of shareholders for 2026, scheduled for January 14, 2026 [5][9] Group 2 - The expected daily related party transactions involve providing warehousing, loading and unloading services, and supply chain management or commercial factoring services to Zhuhai Shiyou Chemical Co., Ltd. [31] - The related party, Zhuhai Shiyou, holds a 41.08% stake in the company, which qualifies as a related party under the Shenzhen Stock Exchange's regulations [35][36] - The independent directors concluded that the proposed transactions are necessary for the company's normal operations, with fair pricing and no harm to the interests of shareholders, especially minority shareholders [37]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688420 证券简称：美腾科技 公告编号：2025-041 天津美腾科技股份有限公司关于2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 是否需要提交股东会审议：否 ● 日常关联交易对上市公司的影响：天津美腾科技股份有限公司（以下简称"公司"）及子公司与关联方 发生的日常关联交易，是公司日常经营活动的需要，符合公司实际经营情况，按照公平、公正、公开的 原则开展，遵循公允、合理的原则，不存在损害公司和公司股东权益的情形，不会影响公司独立性，不 会对关联人形成依赖。交易的发生不会对公司未来财务状况、经营成果、持续经营能力等产生不利影 响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 单位：万元 ■ 注： 1、占同类业务比例计算，分母为截至2024年度经审计同类业务的发生额； 2、上述"2026年预计交易金额"及"2025年年初至2025年12月15日与关联人累计已发生的交易金额"为合 同签订金额（ ...

证券代码：688049 证券简称：炬芯科技 公告编号：2025-076 炬芯科技股份有限公司关于预计2026年度日常关联交易的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次日常关联交易预计事项尚需提交股东会审议。 ● 炬芯科技股份有限公司（以下简称"公司"）本项日常关联交易均是公司及子公司正常生产、经营活动 所必要的，是公司合理利用资源、降低经营成本的重要手段，对公司长远发展有着积极的影响。各项日 常关联交易的定价政策严格遵循公开、公平、公正、等价有偿的一般商业原则，有利于公司相关业务的 开展，不存在损害公司和股东权益的情形。上述交易的发生不会对公司持续经营能力、盈利能力及资产 独立性等产生不利影响。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025年12月26日，公司第二届董事会第二十八次会议审议通过了《关于预计2026年度日常关联交易的议 案》，关联董事叶威廷、叶奕廷、王丽英回避表决，出席会议的非关联董事一致同意该议案。本次日常 关联交易预计事项尚需提交股东会审议，关联 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券简称：688222 证券代码：成都先导 公告编号：2025-058 成都先导药物开发股份有限公司 关于募集资金投资项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则（2025年4月修订）》《上 海证券交易所科创板上市公司自律监管指引第 1 号一一规范运作（2025年5月修订）》等相关规定，成 都先导药物开发股份有限公司（以下简称"成都先导"或"公司"）于 2025 年 12 月 25 日召开第三届董事 会第四次会议，审议通过了《关于募集资金投资项目延期的议案》。同意公司结合目前募集资金投资项 目的实际建设情况和投入进度，在募集资金投资项目实施主体、实施方式、投资用途及投资规模不发生 变更的情况下，对"新分子设计、构建与应用平台建设项目"、"新药研发中心建设项目"达到预定可使用 状态的时间进行调整。上述募集资金投资项目对应的建筑主体工程已顺利通过基础结构验收、顺利完成 封顶，调整后项目实施期限 ...

证券代码：600308 股票简称：华泰股份 编号：2025-038 山东华泰纸业股份有限公司 第十一届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 山东华泰纸业股份有限公司（下称"公司"或"华泰股份"）第十一届董事会第十次会议通知于2025年12月 16日以专人送达及邮件的方式下发给公司9名董事。会议于2025年12月26日以现场与通讯相结合的方式 召开。会议应表决董事9人，实际表决董事9人，公司全体高管人员列席了会议，会议召开符合《公司 法》和《公司章程》的有关规定，所做的决议合法有效。会议由李晓亮董事长主持，经过充分讨论，审 议通过了如下议案： 一、审议通过了《关于日常关联交易预计情况的议案》。 表决结果：7票赞成，0 票反对，0 票弃权。关联董事李晓亮、魏文光回避表决。 此议案已经公司独立董事专门会议审核通过。独立董事专门会议认为公司与控股股东华泰集团有限公司 及其关联方之间发生的日常关联交易是必要的、合理的，符合公司实际情况，该关联交易行为符合国家 的相关规定，在关联交易定价方面公平合理，没 ...

Group 1 - The company held its 16th meeting of the 7th Board of Directors on December 24, 2025, to discuss various proposals [2][3] - The meeting was attended by all 8 directors, confirming its legality and effectiveness [2] - The board approved several proposals, including expected daily related party transactions for 2026 totaling RMB 286.4 million [4][50] Group 2 - The expected daily related party transactions include RMB 250 million with Jining High-tech Holding Group, RMB 20 million with Digital China Group, RMB 11 million with Jidao Technology, RMB 5.3 million with Youchuang Lian Dong Technology, and RMB 100,000 with Youran Jizhi Catering Management [4][50] - The board also approved a proposal to provide a guarantee limit of up to RMB 350 million for its wholly-owned subsidiary, Shenzhen Zanrong Electronics Technology Co., Ltd. [5][41] - The company plans to apply for a total credit limit of up to RMB 1.5 billion from commercial banks for 2026 [7][9] Group 3 - The board approved the use of idle self-owned funds for entrusted wealth management, with a maximum amount of RMB 200 million [10][30] - The purpose of this investment is to improve the efficiency of fund utilization and reduce financial costs [31][36] - The board also proposed to convene the first extraordinary shareholders' meeting of 2026 to review the approved proposals [11][13] Group 4 - The company has established a comprehensive credit guarantee system to ensure operational funding [9] - The expected guarantee limit will be valid for one year from the date of approval by the shareholders' meeting [42] - The company has not engaged in any illegal guarantees or overdue guarantees, maintaining a healthy financial status [47]

Group 1 - The company held its second extraordinary general meeting of shareholders on December 25, 2025, with no proposals being rejected [1][2] - The meeting was conducted in compliance with relevant laws and regulations, and the chairman of the board, Mr. Huang, presided over the meeting [8][17] - The shareholders approved the proposal to lower the conversion price of the "Ben Gang Convertible Bonds" [11] Group 2 - The board of directors convened on December 25, 2025, with all eight directors present, and the meeting was also compliant with legal requirements [18][16] - The board approved several proposals, including the adjustment of the conversion price for the "Ben Gang Convertible Bonds" and the annual salary for senior management for 2024 [19][21] - The conversion price was adjusted from 3.95 yuan per share to 3.29 yuan per share, effective December 26, 2025 [30][31] Group 3 - The company expects to engage in daily related transactions with Ansteel Group and its subsidiaries amounting to approximately 4,124.61 million yuan in 2026, which is 347% of the company's audited net assets [44] - The board approved the expected daily related transactions, which are essential for the company's normal production and operations [50] - Independent directors confirmed that the expected transactions are fair and will not harm the interests of non-related shareholders [51]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600935 证券简称：华塑股份公告编号：2025-086 安徽华塑股份有限公司 第六届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 安徽华塑股份有限公司（以下简称"公司"）于2025年12月25日以现场结合通讯方式召开第六届董事会第 六次会议。本次会议通知及相关材料公司已于2025年12月19日以通讯等方式送达各位董事。本次会议应 出席董事9人，实际出席董事9人，无委托出席董事。 会议由董事长路明先生主持。本次会议的召集、召开及表决程序符合《公司法》《公司章程》及公司 《董事会议事规则》等相关规定，会议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于2026年度日常关联交易预计的议案》 表决结果：赞成票8票，反对票0票，弃权票0票。 本议案已经公司董事会审计委员会审议通过，并召开了公司独立董事专门会议，发表审核意见同意将该 议案提交董事会审议。 此项议案尚需提交公司股东会审议。 （二）审议通过《关于提请召 ...